The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

被引:180
|
作者
Jagust, William J. [1 ]
Landau, Susan M. [1 ]
Koeppe, Robert A. [2 ]
Reiman, Eric M. [3 ]
Chen, Kewei [3 ]
Mathis, Chester A. [4 ]
Price, Julie C. [4 ]
Foster, Norman L. [5 ]
Wang, Angela Y. [5 ]
机构
[1] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA
[2] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA
[3] Banner Alzheimer Inst, Phoenix, AZ USA
[4] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA
[5] Univ Utah, Ctr Alzheimers Care Imaging & Res, Dept Neurol, Salt Lake City, UT USA
关键词
PET imaging; Amyloid; Fluorodeoxyglucose; Mild cognitive impairment; Alzheimer's disease; MILD COGNITIVE IMPAIRMENT; WHITE-MATTER REFERENCE; AMYLOID-BETA; HYPOTHETICAL MODEL; BIOMARKERS; TAU; MODERATE; PATHOLOGY; C-11-PIB; VOLUME;
D O I
10.1016/j.jalz.2015.05.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI. Methods: The PET Core has used [F-18]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [F-18]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition. Results: Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale. Conclusion: The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:757 / 771
页数:15
相关论文
共 50 条
  • [31] Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization
    Petersen, R. C.
    Aisen, P. S.
    Beckett, L. A.
    Donohue, M. C.
    Gamst, A. C.
    Harvey, D. J.
    Jack, C. R., Jr.
    Jagust, W. J.
    Shaw, L. M.
    Toga, A. W.
    Trojanowski, J. Q.
    Weiner, M. W.
    [J]. NEUROLOGY, 2010, 74 (03) : 201 - 209
  • [32] The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods
    Jack, Clifford R., Jr.
    Bernstein, Matt A.
    Fox, Nick C.
    Thompson, Paul
    Alexander, Gene
    Harvey, Danielle
    Borowski, Bret
    Britson, Paula J.
    Whitwell, Jennifer L.
    Ward, Chadwick
    Dale, Anders M.
    Felmlee, Joel P.
    Gunter, Jeffrey L.
    Hill, Derek L. G.
    Killiany, Ron
    Schuff, Norbert
    Fox-Bosetti, Sabrina
    Lin, Chen
    Studholme, Colin
    DeCarli, Charles S.
    Krueger, Gunnar
    Ward, Heidi A.
    Metzger, Gregory J.
    Scott, Katherine T.
    Mallozzi, Richard
    Blezek, Daniel
    Levy, Joshua
    Debbins, Josef P.
    Fleisher, Adam S.
    Albert, Marilyn
    Green, Robert
    Bartzokis, George
    Glover, Gary
    Mugler, John
    Weiner, Michael W.
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2008, 27 (04) : 685 - 691
  • [33] Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans
    Saykin, Andrew J.
    Shen, Li
    Foroud, Tatiana M.
    Potkin, Steven G.
    Swaminathan, Shanker
    Kim, Sungeun
    Risacher, Shannon L.
    Nho, Kwangsik
    Huentelman, Matthew J.
    Craig, David W.
    Thompson, Paul M.
    Stein, Jason L.
    Moore, Jason H.
    Farrer, Lindsay A.
    Green, Robert C.
    Bertram, Lars
    Jack, Clifford R., Jr.
    Weiner, Michael W.
    [J]. ALZHEIMERS & DEMENTIA, 2010, 6 (03) : 265 - 273
  • [34] The longitudinal trajectory of CSF sTREM2: the alzheimer's disease neuroimaging initiative
    Wang, Yu
    Ye, Meijie
    Ji, Qianqian
    Liu, Qi
    Xu, Xiaowei
    Zhan, Yiqiang
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2024, 16 (01)
  • [35] Empirically defining the preclinical stages of the Alzheimer's continuum in the Alzheimer's Disease Neuroimaging Initiative
    Kiselica, Andrew M.
    [J]. PSYCHOGERIATRICS, 2021, 21 (04) : 491 - 502
  • [36] Longitudinal Changes in Cognition and Cerebrovascular Disease in the Alzheimer's Disease Neuroimaging Initiative
    Carmichael, Owen
    Drucker, David
    Schwarz, Christopher
    Fletcher, Evan
    Martinez, Oliver
    Yoshita, Mitsuhiro
    He, Jing
    DeCarli, Charles
    [J]. NEUROLOGY, 2009, 72 (11) : A171 - A171
  • [37] Clinical significance of visually equivocal amyloid PET findings from the Alzheimer's Disease Neuroimaging Initiative cohort
    Oh, Minyoung
    Seo, Minjung
    Oh, Sun Young
    Kim, Heeyoung
    Choi, Byung Wook
    Oh, Jungsu S.
    Kim, Jae Seung
    [J]. NEUROREPORT, 2018, 29 (07) : 553 - 558
  • [38] Neuropathologic Assessment of Alzheimer's Disease Neuroimaging Initiative (ADNI) Participants
    Cairns, Nigel
    Perrin, Richard
    Householder, Erin
    Carter, Deborah
    Vincent, Benjamin
    Morris, John
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2014, 73 (06): : 626 - 626
  • [39] Japanese Alzheimer's Disease Neuroimaging Initiative: Present status and future
    Iwatsubo, Takeshi
    [J]. ALZHEIMERS & DEMENTIA, 2010, 6 (03) : 297 - 299
  • [40] EVALUATION OF DIFFUSION IMAGING PROTOCOLS FOR THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE
    Zhan, L.
    Bernstein, M. A.
    Borowski, B.
    Jack, Clifford R., Jr.
    Thompson, P. M.
    [J]. 2014 IEEE 11th International Symposium on Biomedical Imaging (ISBI), 2014, : 710 - 713